Clinical Trial Update: The Role of Bexarotene in Inducing Susceptibility to Chemotherapy in Metastatic TNBC [Phase 1]

View source ↗

Summary

Phase 1 study evaluating whether bexarotene can increase chemotherapy sensitivity in metastatic triple-negative breast cancer has completed at the National Canc…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Triple-negative Breast Cancer

Drugs mentioned

• Targretin (bexarotene)

Snippet

Sponsor: National Cancer Centre, Singapore | Conditions: Metastatic Triple-Negative Breast Carcinoma | Phase 1 | Status: COMPLETED